Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus

Medical Care

Volumn 44, Issue 10, 2006, Pages 893-899

  Munakata, Julie ^a   Benner, Joshua S ^a   Becker, Stephen ^b   Dezii, Christopher M ^c   Hazard, Elisabeth H ^a   Tierce, Jonothan C ^a  

^a ValueMedics Research LLC   (United States)

^b GENZYME CORPORATION   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; Compliance; Cost effectiveness; HIV; Markov model

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; THEORETICAL MODEL; UNITED STATES;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 33749033333     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000233679.20898.e9     Document Type: Article

References (50)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-1503.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
3. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
4. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
5. Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2001;2:52-58.
6. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med. 1993;329:2029-2032.
7. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-253.
8. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200-209.
9. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 11-10-2003.
10. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000; 14:357-366.
11. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-125.
12. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999; 13:1099-1107.
13. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000; 23:360-361.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
15. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183.
16. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
17. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(Suppl 1):S2-S10.
18. Schackman BR, Finkelstein R, Neukermans CP, et al. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care. 2005; 17:927-937.
19. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
20. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8:585-594.
21. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-585.
22. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
23. Brett-Smith H, Reynolds L, Bessen L, et al. Two-year analysis of stavudine extended-release/prolonged release capsules (xr/prc) as compared to stavudine immediate-release (ir): efficacy and safety. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003.
24. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
25. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-1968.
26. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93.
27. Walensky RP, Goldie SJ, Sax PE, et al. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002;31:27-37.
28. Raboud JM, Harris M, Rae S, et al. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 2002;3:118-124.
29. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126:946-954.
30. National Center for Health Statistics. Vital Statistics of the United States, 1995: Preprint of Volume II, Mortality, Part A, Section 6: life tables. DHHS Publication no. (PHS) 98-1147. Hyattsville, MD: U.S. Department of Health and Human Services; 1998.
31. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
32. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002;7:257-266.
33. Stansell J, Barrett J, DeGuzman C, et al. Incremental costs of HIV suppression in HIV therapeutic failure. 7th Conference on Retroviruses and Opportunistic Infections; 2000.
34. Scalera A, Bayoumi AM, Oh P, et al. Clinical and economic implications of non-adherence to HAART in HIV infection. Disease Management Health Outcomes. 2002;10:85-91.
35. Drug Topics Red Book. Montvale: Medical Economics; 2002.
36. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res. 1999;8: 471-480.
37. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16:54-62.
38. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care. 1996;34:44-57.
39. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
40. Simoni JM, Frick PA, Pantalone DW, et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003; 11:185-198.
41. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221-228.
42. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000;15:841-847.
43. Knobel H, Carmona A, Lopez JL, et al. [Adherence to very active antiretroviral treatment: impact of individualized assessment]. Enferm Infecc Microbiol Clin. 1999;17:78-81.
44. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632-641.
45. Markowitz M. Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. JAMA. 2000;283:250-251.
46. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
47. Enriquez M, Lackey NR, O'Connor MC, et al. Successful adherence after multiple HIV treatment failures. J Adv Nurs. 2004;45:438-446.
48. HIV/AIDS Surveillance Report. US HIV and AIDS cases reported through December 2001;13(12).
49. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S112-S117.
50. Brook MG, Dale A, Tomlinson D, et al. Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units. AIDS Patient Care STDS. 2001;15:491-494.